A regulatory/scientific, advisory meeting has been performed at the MPA on the 25.3.13.
The results from the recently concluded clinical study and the design of the planned phase III were discussed. The advice from the MPA is not binding but gives a valuable direction how to continue the work. They were satisfied with our plans.
